drugset
drugset / Trial / NCT07649395

A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient

NCT07649395 ↗

Completed 75 enrolled Mei Feng
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma (CSCC) patients during concurrent chemoradiotherapy.

Timeline

Start
2021-02-01
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic — —

Indications

cervical squamous cell carcinoma